• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1
ctDNA Monitoring for Small Cell Lung Cancer: Ready for Prime Time?ctDNA 监测在小细胞肺癌中的应用：是否已准备好成为主流？
Clin Cancer Res. 2023 Jun 13;29(12):2176-2178. doi: 10.1158/1078-0432.CCR-23-0420.
2
Prognostic value of circulating tumor DNA using target next-generation sequencing in extensive-stage small-cell lung cancer.广泛期小细胞肺癌中使用靶向二代测序的循环肿瘤 DNA 的预后价值。
Lung Cancer. 2023 Apr;178:11-19. doi: 10.1016/j.lungcan.2023.01.015. Epub 2023 Feb 2.
3
[Analysis of the feasibility and prognostic value of circulating tumor DNA in detecting gene mutations in small cell lung cancer].循环肿瘤DNA检测小细胞肺癌基因突变的可行性及预后价值分析
Zhonghua Yi Xue Za Zhi. 2020 Dec 8;100(45):3614-3621. doi: 10.3760/cma.j.cn112137-20200504-01412.
4
Circulating Tumor DNA Profiling in Small-Cell Lung Cancer Identifies Potentially Targetable Alterations.循环肿瘤 DNA 分析在小细胞肺癌中鉴定出潜在的可靶向改变。
Clin Cancer Res. 2019 Oct 15;25(20):6119-6126. doi: 10.1158/1078-0432.CCR-19-0879. Epub 2019 Jul 12.
5
Dynamics of Sequence and Structural Cell-Free DNA Landscapes in Small-Cell Lung Cancer.小细胞肺癌中游离 DNA 序列和结构的动态变化。
Clin Cancer Res. 2023 Jun 13;29(12):2310-2323. doi: 10.1158/1078-0432.CCR-22-2242.
6
Targeted sequencing of plasma cell-free DNA to predict response to PD1 inhibitors in advanced non-small cell lung cancer.血浆游离 DNA 靶向测序预测晚期非小细胞肺癌对 PD1 抑制剂的反应。
Lung Cancer. 2019 Nov;137:1-6. doi: 10.1016/j.lungcan.2019.09.005. Epub 2019 Sep 6.
7
Integrating circulating-free DNA (cfDNA) analysis into clinical practice: opportunities and challenges.将循环游离 DNA（cfDNA）分析纳入临床实践：机遇与挑战。
Br J Cancer. 2022 Sep;127(4):592-602. doi: 10.1038/s41416-022-01776-9. Epub 2022 Mar 26.
8
Clinical Implications of Circulating Tumor DNA Tumor Mutational Burden (ctDNA TMB) in Non-Small Cell Lung Cancer.循环肿瘤 DNA 肿瘤突变负荷（ctDNA TMB）在非小细胞肺癌中的临床意义。
Oncologist. 2019 Jun;24(6):820-828. doi: 10.1634/theoncologist.2018-0433. Epub 2019 Mar 13.
9
The Feasibility of Using Biomarkers Derived from Circulating Tumor DNA Sequencing as Predictive Classifiers in Patients with Small-Cell Lung Cancer.基于循环肿瘤 DNA 测序的生物标志物用于小细胞肺癌患者预测分类器的可行性。
Cancer Res Treat. 2022 Jul;54(3):753-766. doi: 10.4143/crt.2021.905. Epub 2021 Oct 5.
10
Clinical Utility of Liquid Biopsy (Cell-free DNA) Based EGFR Mutation Detection Post treatment Initiation as a Disease Monitoring Tool in Patients With Advanced EGFR-mutant NSCLC.液体活检（游离 DNA）在晚期 EGFR 突变型 NSCLC 患者治疗起始后作为疾病监测工具的临床应用价值：基于 EGFR 基因突变检测。
Clin Lung Cancer. 2022 Jul;23(5):410-418. doi: 10.1016/j.cllc.2022.04.002. Epub 2022 Apr 30.

引用本文的文献

1
Adebrelimab in Small Cell Lung Cancer: From Current Advances to Emerging Combination Strategy and Challenge.阿得贝利单抗治疗小细胞肺癌：从当前进展到新兴联合策略及挑战
Biologics. 2025 May 31;19:365-377. doi: 10.2147/BTT.S500470. eCollection 2025.
2
Novel strategy for comprehensive therapy with sustainably complete response in a patient with limited-stage small cell lung cancer: a case report.局限期小细胞肺癌患者综合治疗并持续完全缓解的新策略：一例病例报告
J Int Med Res. 2024 Dec;52(12):3000605241305429. doi: 10.1177/03000605241305429.
3
Sintilimab combined with anlotinib and chemotherapy as second-line or later therapy in extensive-stage small cell lung cancer: a phase II clinical trial.信迪利单抗联合安罗替尼和化疗二线或后线治疗广泛期小细胞肺癌的 II 期临床研究。
Signal Transduct Target Ther. 2024 Sep 16;9(1):241. doi: 10.1038/s41392-024-01957-3.
4
Advances in predictive biomarkers associated with immunotherapy in extensive-stage small cell lung cancer.广泛期小细胞肺癌免疫治疗相关预测生物标志物的进展
Cell Biosci. 2024 Sep 12;14(1):117. doi: 10.1186/s13578-024-01283-9.
5
Predictive biomarkers for immunotherapy response in extensive-stage SCLC.广泛期小细胞肺癌免疫治疗反应的预测生物标志物。
J Cancer Res Clin Oncol. 2024 Jan 20;150(1):22. doi: 10.1007/s00432-023-05544-x.

本文引用的文献

1
Dynamics of Sequence and Structural Cell-Free DNA Landscapes in Small-Cell Lung Cancer.小细胞肺癌中游离 DNA 序列和结构的动态变化。
Clin Cancer Res. 2023 Jun 13;29(12):2310-2323. doi: 10.1158/1078-0432.CCR-22-2242.
2
Circulating Tumor DNA as a Prognostic Determinant in Small Cell Lung Cancer Patients Receiving Atezolizumab.循环肿瘤DNA作为接受阿替唑单抗治疗的小细胞肺癌患者的预后决定因素
J Clin Med. 2020 Nov 27;9(12):3861. doi: 10.3390/jcm9123861.
3
White blood cell and cell-free DNA analyses for detection of residual disease in gastric cancer.胃癌残留病灶检测的白细胞和游离 DNA 分析。
Nat Commun. 2020 Jan 27;11(1):525. doi: 10.1038/s41467-020-14310-3.
4
COSMIC: the Catalogue Of Somatic Mutations In Cancer.COSMIC：癌症体细胞突变目录。
Nucleic Acids Res. 2019 Jan 8;47(D1):D941-D947. doi: 10.1093/nar/gky1015.
5
Circulating tumor DNA analysis depicts subclonal architecture and genomic evolution of small cell lung cancer.循环肿瘤 DNA 分析描绘了小细胞肺癌的亚克隆结构和基因组进化。
Nat Commun. 2018 Aug 6;9(1):3114. doi: 10.1038/s41467-018-05327-w.
6
Longitudinal Cell-Free DNA Analysis in Patients with Small Cell Lung Cancer Reveals Dynamic Insights into Treatment Efficacy and Disease Relapse.纵向分析小细胞肺癌患者的游离 DNA 可深入了解治疗效果和疾病复发的动态。
J Thorac Oncol. 2018 Jan;13(1):112-123. doi: 10.1016/j.jtho.2017.09.1951. Epub 2017 Sep 23.
7
Early Detection of Molecular Residual Disease in Localized Lung Cancer by Circulating Tumor DNA Profiling.局部肺癌中循环肿瘤 DNA 谱分析的分子残留疾病的早期检测。
Cancer Discov. 2017 Dec;7(12):1394-1403. doi: 10.1158/2159-8290.CD-17-0716. Epub 2017 Sep 24.
8
Direct detection of early-stage cancers using circulating tumor DNA.利用循环肿瘤DNA直接检测早期癌症。
Sci Transl Med. 2017 Aug 16;9(403). doi: 10.1126/scitranslmed.aan2415.
9
CNVkit: Genome-Wide Copy Number Detection and Visualization from Targeted DNA Sequencing.CNVkit：通过靶向DNA测序进行全基因组拷贝数检测与可视化
PLoS Comput Biol. 2016 Apr 21;12(4):e1004873. doi: 10.1371/journal.pcbi.1004873. eCollection 2016 Apr.
10
Comprehensive genomic profiles of small cell lung cancer.全面基因组分析小细胞肺癌
Nature. 2015 Aug 6;524(7563):47-53. doi: 10.1038/nature14664. Epub 2015 Jul 13.

ctDNA 监测在小细胞肺癌中的应用：是否已准备好成为主流？

ctDNA Monitoring for Small Cell Lung Cancer: Ready for Prime Time?

机构信息

Department of Thoracic Oncology, Moffitt Cancer Center and Research Institute, Tampa, Florida.

Department of Oncologic Sciences, Morsani College of Medicine, University of South Florida, Tampa, Florida.

出版信息

Clin Cancer Res. 2023 Jun 13;29(12):2176-2178. doi: 10.1158/1078-0432.CCR-23-0420.

DOI:10.1158/1078-0432.CCR-23-0420
PMID:37097069
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10330146/
Abstract

Small cell lung cancer (SCLC) is the deadliest form of lung cancer and has few precision medicine approaches available. A recent study analyzed circulating tumor DNA (ctDNA) in 33 patients with extensive-stage SCLC and showed that ctDNA levels and response patterns correlate strongly with clinical response and survival outcomes. See related article by Sivapalan et al., p. 2310.

摘要

小细胞肺癌（SCLC）是肺癌中最致命的形式，可用的精准医疗方法很少。最近的一项研究分析了 33 例广泛期 SCLC 患者的循环肿瘤 DNA（ctDNA），结果表明 ctDNA 水平和反应模式与临床反应和生存结果密切相关。见 Sivapalan 等人的相关文章，第 2310 页。